Gilead to Acquire Myogen

Article

Gilead Sciences, of Foster City, CA (www.gilad.com), has agreed to acquire Myogen for about $2.5 billion, a move aimed at gaining ownership of Ambrisentan, a treatment for pulmonary arterial hypertension that is in late-stage clinical trials.

Gilead Sciences, of Foster City, CA (www.gilad.com), has agreed to acquire Myogen for about $2.5 billion, a move aimed at gaining ownership of Ambrisentan, a treatment for pulmonary arterial hypertension that is in late-stage clinical trials. The drug is Myogen’s lead product candidate. Myogen expects to file a new-drug application for Ambrisentan with the FDA as early as the fourth quarter. British drug maker GlaxoSmithKline holds rights to the product outside of the US.

Recent Videos
US tariff rate rising , trade policy , business graph and dollars banknote , tax calculation change | Image Credit: © janews094 - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.